- Home
- DAVE vs MIRM Comparison
DAVE vs MIRM Comparison
Compare DAVE & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVE
- MIRM
- Stock Information
- Founded
- DAVE 2017
- MIRM 2018
- Country
- DAVE United States
- MIRM United States
- Employees
- DAVE N/A
- MIRM N/A
- Industry
- DAVE Retail: Computer Software & Peripheral Equipment
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- DAVE Technology
- MIRM Health Care
- Exchange
- DAVE Nasdaq
- MIRM Nasdaq
- Market Cap
- DAVE 2.9B
- MIRM 2.5B
- IPO Year
- DAVE N/A
- MIRM 2019
- Fundamental
- Price
- DAVE $239.87
- MIRM $51.12
- Analyst Decision
- DAVE Strong Buy
- MIRM Strong Buy
- Analyst Count
- DAVE 6
- MIRM 9
- Target Price
- DAVE $243.83
- MIRM $66.22
- AVG Volume (30 Days)
- DAVE 599.5K
- MIRM 351.2K
- Earning Date
- DAVE 08-06-2025
- MIRM 08-11-2025
- Dividend Yield
- DAVE N/A
- MIRM N/A
- EPS Growth
- DAVE N/A
- MIRM N/A
- EPS
- DAVE 3.70
- MIRM N/A
- Revenue
- DAVE $381,425,000.00
- MIRM $379,251,000.00
- Revenue This Year
- DAVE $37.77
- MIRM $36.76
- Revenue Next Year
- DAVE $18.45
- MIRM $17.48
- P/E Ratio
- DAVE $64.92
- MIRM N/A
- Revenue Growth
- DAVE 39.31
- MIRM 69.31
- 52 Week Low
- DAVE $28.74
- MIRM $36.20
- 52 Week High
- DAVE $286.45
- MIRM $54.78
- Technical
- Relative Strength Index (RSI)
- DAVE 58.07
- MIRM 50.28
- Support Level
- DAVE $189.00
- MIRM $50.92
- Resistance Level
- DAVE $217.70
- MIRM $52.63
- Average True Range (ATR)
- DAVE 17.61
- MIRM 1.49
- MACD
- DAVE 0.73
- MIRM -0.35
- Stochastic Oscillator
- DAVE 92.32
- MIRM 5.30
About DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.